SCHEMBL6182736

SCHEMBL6182736

Cc1ccc(C(=O)CCl)cc1F

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
GSK3B P49841 3/20 0.47
KCNQ3 O43525 2/20 0.47
KCNQ2 O43526 2/20 0.47
KCNE1 P15382 2/20 0.47
KCNQ1 P51787 2/20 0.47
KCNQ5 Q9NR82 1/20 0.47
ALDH1A1 P00352 8/20 0.44
HIF1A Q16665 2/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 2/20 0.44
POLB P06746 2/20 0.44
TRPA1 O75762 1/20 0.44
MAPK1 P28482 1/20 0.44
TP53 P04637 2/20 0.43
KMT2A Q03164 3/20 0.43
MTOR P42345 1/20 0.42
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9720643 0.83 HDAC1 (0.58) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL21006684 0.83 HDAC1 (0.58) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL8424293 0.82 GSK3B (0.52) GSK3BALDH1A1HIF1ALMNAHTT
SCHEMBL29464070 0.82 CES2 (0.59) GSK3BKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL247898 0.82 CES2 (0.59) GSK3BKCNQ3KCNQ2KCNE1KCNQ1
SCHEMBL14684053 0.81 HDAC1 (0.56) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL4345488 0.81 HDAC1 (0.56) HDAC1HDAC6GSK3BKCNQ3KCNQ2
SCHEMBL5461438 0.80 MAPT (0.57) HDAC1HDAC6ALDH1A1LMNAHTT
SCHEMBL16064398 0.80 HDAC1 (0.59) HDAC1HDAC6KCNQ3KCNQ2KCNE1
SCHEMBL5455143 0.79 KDM4E (0.49) GSK3BALDH1A1HIF1ALMNATRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507530-B1 DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS HOFFMANN LA ROCHE (CH) 2005-11-02 EP disclosed
EP-1507530-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-02-23 EP disclosed
US-6818663-B2 AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS HOFFMANN-LA ROCHES 2004-11-16 US disclosed
US-20040006058-A1 DIAMINOTHIAZOLES CHU XIN-JIE (US) 2004-01-08 US disclosed
WO-2003097048-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-27 WO disclosed
US-4762844-A ANIMAL GROWTH REGULATORS BAYER AKTIENGESELLSCHAFT (DE) 1988-08-09 US disclosed
EP-0181588-A2 Alkyl-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids, process for their preparation, and antibacterial agents containing them BAYER AG (DE) 1986-05-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006058-A1 DIAMINOTHIAZOLES CDK4, CDK1, CDK2 HDAC1 117/4885HDAC6 450/4885GSK3B 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.